Aclaris Therapeutics (ACRS) Intangibles (2017 - 2023)

Aclaris Therapeutics' Intangibles history runs 7 years deep, the most recent figure standing at $751000.0 for Q4 2023.

• On a quarterly basis, Intangibles fell 89.82% year-over-year to $751000.0 in Q4 2023; TTM through Dec 2023 was $751000.0, a 89.82% decrease from a year earlier, with the FY2023 full-year figure at $751000.0, down 89.82% from the prior year.
• Intangibles retreated to $751000.0 in Q4 2023 per ACRS's latest filing, from $7.4 million in the prior quarter.
• Across five years, Intangibles topped out at $73.8 million in Q1 2019 and bottomed at $751000.0 in Q4 2023.
• The 5-year median for Intangibles is $7.1 million (2020), against an average of $13.3 million.
• Across the five-year window, Intangibles jumped 906.75% in 2019 and plunged 90.0% in 2020, its largest moves.
• Year by year, Intangibles stood at $7.2 million in 2019, then decreased by 1.06% to $7.1 million in 2020, then slipped by 1.05% to $7.0 million in 2021, then climbed by 4.71% to $7.4 million in 2022, then slumped by 89.82% to $751000.0 in 2023.
• Per Business Quant, the three latest ACRS Intangibles figures stand at $751000.0 (Q4 2023), $7.4 million (Q3 2023), and $6.9 million (Q2 2023).